InvestorsHub Logo
Followers 86
Posts 12714
Boards Moderated 0
Alias Born 10/12/2010

Re: north40000 post# 277126

Monday, 10/24/2016 7:30:37 PM

Monday, October 24, 2016 7:30:37 PM

Post# of 345756
Very interesting article North....and specifically this line :

"Payers typically cover NCCN-listed uses for cancer drugs, even if they’re not specifically approved by the FDA, and this would allow doctors to go ahead and prescribe the regimen."

I wonder now, since Peregrine has NCCN on PS Targeting....why Merck needs approval from NCCN

"Bavituximab is a first-in-class phosphatidylserine (PS)-targeting monoclonal antibody that is the cornerstone of a broad clinical
pipeline."
-- Big Pharmas nightmare... unless they are fortunate enough to have The Bavi Edge!

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CDMO News